Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Moody's Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Moody's Corporation trades at $493.7 (market cap $86.42B). The key difference: Moody's Corporation is far larger — about 10.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Moody's Corporation pays a 0.83% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MCO | |
|---|---|---|
Market Cap | $8.04B | $86.42B |
Sector | Health | Financials |
52-Week High | $339.75 | $539.61 |
52-Week Low | $241.71 | $412.23 |
Enterprise Value | $7.85B | $92.22B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
MCO trades at $495.72, up 1.73% today, with strong technical momentum as price hovers near pivot point resistance at $496. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while recent AI platform expansions signal growth initiatives. Analyst consensus remains bullish with a $539.40 price target, though valuation multiples appear elevated.
Outlook remains positive given earnings momentum and strategic AI investments, but high P/E of 35.56 presents valuation risk. Key catalysts include Q2 2026 earnings release on July 22, while regulatory scrutiny and debt market sensitivity represent ongoing headwinds for the credit ratings leader.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
